Prosecution Insights
Last updated: April 19, 2026
Application No. 17/835,719

Methods for Purification of Messenger RNA

Final Rejection §DP
Filed
Jun 08, 2022
Examiner
GUSSOW, ANNE
Art Unit
1683
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Translate Bio, Inc.
OA Round
9 (Final)
58%
Grant Probability
Moderate
10-11
OA Rounds
3y 7m
To Grant
99%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allow Rate
186 granted / 320 resolved
-1.9% vs TC avg
Strong +44% interview lift
Without
With
+44.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
68 currently pending
Career history
388
Total Applications
across all art units

Statute-Specific Performance

§101
7.6%
-32.4% vs TC avg
§103
28.2%
-11.8% vs TC avg
§102
17.4%
-22.6% vs TC avg
§112
34.1%
-5.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 320 resolved cases

Office Action

§DP
Detailed Action ► The applicant's response (filed 17 FEB 026) to the Office Action has been entered. Following the entry of the claim amendment(s), Claim(s) 32-50 is/are pending. Rejections and/or objections not reiterated from the previous office action are hereby withdrawn. The following rejections and/or objections are either newly applied or reiterated. They constitute the complete set presently being applied to the instant application. ► The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. NSODP rejections ► Claims 32-41, 45-47, and 49-50 are rejected on the ground of non-statutory double patenting as being unpatentable over claims 1-15 of U.S. Patent No. 12,234,446 (hereinafter "the '446 patent") in view of Pokrovskaya et al. (1994, Analytical Biochemistry; hereinafter "Pokrovskaya") and Weide et al. (2008, Journal of Immunology; hereinafter "Weide") for the reason(s) of record. ► Claims 42-44 and 48 are rejected on the ground of nonstatutory double patenting, as allegedly being unpatentable over claims 1-15 of the '446 patent in view of Pokrovskaya and Weide and further in view of Melton and Krieg (1984, Nucleic Acids Research; hereinafter "Melton") for the reason(s) of record. Response to applicant Response ► The applicant has traversed the double patenting rejection of at least Claim 32 over US -446’ arguing that Pokrovskaya “teaches away” because they teach a LiCl based method of extraction. In response the examiner notes that the MPEP at 2122 addresses ‘teaching away’ as a important concept in patent law related to obviousness rejections. A prior art reference is said to ‘teach away’ from the claimed invention if it criticizes, discredits, or otherwise discourages the solution claimed. Such, is not the case in the instant application. An example of a “teaching away” constitutes a reference teaching that a certain method (e.g. using a specific material) will fail or is unsafe. The applicant has also traversed the use of Weide, alone or in combination with Pokrovskaya, because these references fail to teach the required motivation to combine. In response the examiner points to motivation provided in the Non-final Office Action mailed 10 OCT 2025 : which reads. “The PHOSITA would have been motivated to make the modification recited above in order to produce a "large amount" pharmaceutical grade mRNA at scale” As such, the ODP rejection has been reconsidered in light of applicant’s response, and is hereby maintained over US-446’ in view of with Pokrovskaya and Weide. Conclusion C1. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 C.F.R. § 1.136(a). A SHORTENED STATUTORY PERIOD FOR RESPONSE TO THIS FINAL ACTION IS SET TO EXPIRE THREE MONTHS FROM THE DATE OF THIS ACTION. IN THE EVENT A FIRST RESPONSE IS FILED WITHIN TWO MONTHS OF THE MAILING DATE OF THIS FINAL ACTION AND THE ADVISORY ACTION IS NOT MAILED UNTIL AFTER THE END OF THE THREE-MONTH SHORTENED STATUTORY PERIOD, THEN THE SHORTENED STATUTORY PERIOD WILL EXPIRE ON THE DATE THE ADVISORY ACTION IS MAILED, AND ANY EXTENSION FEE PURSUANT TO 37 C.F.R. § 1.136(a) WILL BE CALCULATED FROM THE MAILING DATE OF THE ADVISORY ACTION. IN NO EVENT WILL THE STATUTORY PERIOD FOR RESPONSE EXPIRE LATER THAN SIX MONTHS FROM THE DATE OF THIS FINAL ACTION. C2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ethan Whisenant whose telephone number is (571) 272-0754. The examiner can normally be reached Monday-Friday from 8:30 am -5:30 pm EST or any time via voice mail. If repeated attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Gussow, can be reached at (571) 272-6047. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. The Central Fax number for the USPTO is (571) 273-8300. Please note that the faxing of papers must conform with the Notice to Comply published in the Official Gazette, 1096 OG 30 (November 15, 1989). Information regarding the status of an application may be obtained from the Patent Center system. Status information for published applications may be obtained through the Patent Center. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ETHAN C WHISENANT/Primary Examiner, Art Unit 1683 ethan.whisenant@uspto.gov
Read full office action

Prosecution Timeline

Jun 08, 2022
Application Filed
Sep 23, 2022
Non-Final Rejection — §DP
Nov 08, 2022
Examiner Interview Summary
Dec 28, 2022
Response Filed
Jan 24, 2023
Final Rejection — §DP
Apr 28, 2023
Request for Continued Examination
May 02, 2023
Response after Non-Final Action
Jun 15, 2023
Non-Final Rejection — §DP
Sep 21, 2023
Response Filed
Oct 28, 2023
Final Rejection — §DP
Feb 02, 2024
Response after Non-Final Action
Mar 04, 2024
Notice of Allowance
Mar 16, 2024
Response after Non-Final Action
Mar 16, 2024
Non-Final Rejection — §DP
Mar 16, 2024
Response after Non-Final Action
Jun 21, 2024
Response Filed
Sep 25, 2024
Non-Final Rejection — §DP
Dec 26, 2024
Response Filed
Apr 05, 2025
Non-Final Rejection — §DP
Jul 14, 2025
Response Filed
Oct 08, 2025
Non-Final Rejection — §DP
Jan 12, 2026
Response Filed
Feb 04, 2026
Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595507
METHOD AND PRODUCT
2y 5m to grant Granted Apr 07, 2026
Patent 12590170
RECOMBINANT HUMAN ANTIBODIES THAT INHIBIT THE HUMAN TISSUE KALLIKREIN 7 (KLK7) AND THEIR USE AGAINST DISEASES THAT CAUSE DESQUAMATION OF THE SKIN
2y 5m to grant Granted Mar 31, 2026
Patent 12559770
MSBI SEQUENCES AS AN EARLY MARKER FOR THE FUTURE DEVELOPMENT OF CANCER AND DISEASES OF THE CNS AND AS A TARGET FOR THE TREATMENT AND PREVENTION OF THESE DISEASES
2y 5m to grant Granted Feb 24, 2026
Patent 12545955
ANALYSIS OF A POLYMER
2y 5m to grant Granted Feb 10, 2026
Patent 12545956
ANALYSIS OF A POLYMER
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

10-11
Expected OA Rounds
58%
Grant Probability
99%
With Interview (+44.1%)
3y 7m
Median Time to Grant
High
PTA Risk
Based on 320 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month